DBP launches a new website
Double Bond Pharmaceutical has now launched a new, more modern website where staff members themselves appear in front of the camera.
"We are a modern and innovative company that invites everyone to follow us in our daily lives and thought that the website should reflect this. - Igor Lokot, CEO of Double Bond Pharmaceutical comments, "Communication with the outside world is important to us, and the website is the first source of information for many new partners, customers and investors. We are proud to be consequent and show who we are."
For more info, contact
Igor Lokot, CEO
Information on Double Bond Pharmaceutical International AB
DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.